The medications have been shown to work most effectively when people are at their top doses for many months
Diabetes Care 45 , 12011210 (2022)
Recommendations- To take advantage of the opportunities, The Business Research Company recommends the GLP-1 receptor agonist companies to focus on expanding oral and patient-centric GLP-1 therapies, focus on advancing dual GLP-1/GIP therapies for superior obesity outcomes, focus on developing dual GLP-1/glucagon agonists for metabolic liver disease, focus on expanding semaglutide and tirzepatide offerings to capture high-growth segments, focus on expanding oral glp-1 therapies to capture rapidly growing market demand, focus on wind power systems as the fastest-growing segment, focus on variable speed drives to capture high-growth opportunities, focus on expanding distribution channels across non-traditional care settings, focus on strategic pricing to enhance market access and competitiveness, focus on educating healthcare providers to drive adoption, focus on patient-centric awareness campaigns to expand engagement, focus on expanding GLP-1 access through other users channels.
Vision loss/changes: Recent studies have linked semaglutide to non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition
Post RM
This is why vitamin C deficiency causes scurvy, with impaired wound healing and capillary fragility
